This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
As Invitrogen seeks to rebound from a year made difficult primarily by the large number of acquisitions it made in 2004 and 2005, a company official said this week that the firm would not shy away from acquisitions, though they would be fewer and smaller than in the past.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.